Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 549

2.

Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.

Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, Dattagupta S, Thulkar S.

Urology. 2008 Oct;72(4):859-63. doi: 10.1016/j.urology.2008.01.014. Epub 2008 Mar 10.

PMID:
18329078
3.

Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.

Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.

BJU Int. 2008 Aug;102(4):452-8. doi: 10.1111/j.1464-410X.2008.07633.x. Epub 2008 May 12.

4.

Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.

Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB.

J Urol. 1998 Apr;159(4):1243-6.

PMID:
9507845
6.
7.

Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse.

Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL.

Clin Prostate Cancer. 2004 Dec;3(3):174-81.

PMID:
15636684
8.

Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.

Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E, Ferrando U, Regge D.

Clin Radiol. 2008 Aug;63(8):871-9. doi: 10.1016/j.crad.2007.10.020.

PMID:
18625351
9.

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.

Pearson JD, Luderer AA, Metter EJ, Partin AW, Chan DW, Fozard JL, Carter HB.

Urology. 1996 Dec;48(6A Suppl):4-9.

PMID:
8973693
10.

Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.

Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT.

Urology. 2009 Jul;74(1):177-83. doi: 10.1016/j.urology.2008.10.062. Epub 2009 May 9.

PMID:
19428074
11.

Prostate-specific antigen levels as a predictor of lethal prostate cancer.

Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L; Scandinavian Prostate Cancer Group Study No. 4.

J Natl Cancer Inst. 2007 Apr 4;99(7):526-32.

PMID:
17405997
12.
13.
14.
15.
16.

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.

Prostate. 2005 Aug 1;64(3):240-5.

PMID:
15712213
17.

The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.

Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT.

BJU Int. 2007 Apr;99(4):786-93. Epub 2007 Jan 12.

18.

Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.

Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM, Joe BN, Kurhanewicz J.

AJR Am J Roentgenol. 2007 Mar;188(3):812-6.

PMID:
17312072
20.

Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.

Nishimoto K, Nakashima J, Hashiguchi A, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M, Murai M.

Int J Urol. 2008 Jun;15(6):520-3. doi: 10.1111/j.1442-2042.2008.02042.x. Epub 2008 Apr 15.

Supplemental Content

Support Center